Home › Upcoming votes › Supernus Pharmaceuticals, Inc.
This meeting took place on October 15, 2026. Supernus Pharmaceuticals, Inc. reported the official results on Form 8-K, filed October 15, 2026 (read it on EDGAR); they are listed below. How funds voted appears on the company page after funds file Form N-PX, by August 31 after the proxy season ends on June 30.
The deadline as the proxy statement states it: “Votes submitted via the internet must be received by 11:59 p.m. Eastern Time on October 14, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGARSupernus Pharmaceuticals, Inc.: past votes
Ballot: see the proxy statement. The items on this ballot could not be read from the filing with enough confidence to list them here. Read the proxy statement.
From Supernus Pharmaceuticals, Inc.’s Form 8-K, filed June 17, 2025, for the meeting held June 16, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Carolee Barlow, M.D., Ph.D | 97% | — |
| Elect Director: Jack A. Khattar | 98% | — |
| 2. To approve, on a non-binding basis, the compensation paid to our named executive officers | 96% | — |
| 3. Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2 | 99.3% | — |
The five managers that reported the most shares voted at Supernus Pharmaceuticals, Inc.’s June 16, 2025 meeting, from their Form N-PX filings. This is how they voted then; it says nothing about how they will vote this time. Every manager’s vote.
| Item | BlackRock | Vanguard | State Street | MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST | American Century |
|---|---|---|---|---|---|
| Elect Director: Carolee Barlow, M.D., Ph.D | For | For | For | — | For |
| Elect Director: Jack A. Khattar | For | For | For | — | For |
| 2. To approve, on a non-binding basis, the compensation paid to our named executive officers | For | For | For | For | For |
| 3. Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year e | For | For | For | — | For |
| To consider and vote upon a stockholder proposal, if included in our Proxy Statement for the Annual Meeting of Stockhold | Abstain | Mixed | — | — | — |
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| 1. Adoption of the Merger Agreement (such proposal, the "Supernus Merger Proposal") | 99.5% | — |
| 2. To approve, on a non-binding basis, the compensation that (i) will become payable to, and (ii) may become upon a termination of, the Comp | 67% | — |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.